Drug Development

KD Trust backs research to find a cure for hemophilia

Published in Gene Therapy Weekly, October 14th, 2004

In a bid to find a way of eliminating hemophilia and other bleeding disorders, the Katharine Dormandy Trust for Haemophilia & Allied Disorders (KD Trust) is launching a UKP5 million 'Haemappeal' campaign, focusing on research for a cure into this lifelong, and extremely costly, medical condition.

Very recent developments in gene therapy for hemophilia in the UK have resulted in a cure in the laboratory. Ted Tuddenham, director of MRC Haemostasis and Thrombosis Research Group, Imperial College and chairman of the KD Trust, said, "The KD Trust has reviewed results of key worldwide gene therapy for hemophilia research projects, noting the strengths, weaknesses and wide...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-10-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry